Better ways to measure liver scarring in NASH
Part of Digestive system clinical trials.
This study aims to develop better ways to measure how much fibrosis (scarring) in the liver improves after treatment for NASH (fatty liver with inflammation). If you have moderate to severe liver scarring from NASH, this research could help doctors track your condition more precisely, which may lead to more effective care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have had a liver biopsy showing NASH (fatty liver with inflammation) and fibrosis (scarring) at stage F2, F3, or F4 (moderate to severe).
- You do not have other liver diseases like viral hepatitis, alcoholic liver disease, autoimmune liver disease, genetic metabolic liver disease, or drug-induced liver injury.
- You are not pregnant.
- You do not have liver cancer, decompensated cirrhosis (with complications), another cancer, or a history of liver transplantation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study aims to find a simple way to detect liver fibrosis, a condition where the liver becomes scarred, in people who have risk factors like being overweight, having type 2 diabetes, or drinking alcohol heavily. By identifying fibrosis early, it may help prevent more serious liver problems.
This trial tests whether a very low calorie ketogenic diet (a strict low-carb, high-fat diet) can help people with non-alcoholic steatohepatitis (NASH) who have liver scarring. Participants will follow this diet for a year and have two liver biopsies to see if their liver health improves.
This study looks at whether simple blood tests can help predict liver scarring (fibrosis) in people with fatty liver disease. If you join, you'll have a quick, non-invasive scan of your liver to check for fat and scarring.
This study looks at better ways to predict significant liver fibrosis (scarring) in people with chronic hepatitis B or non-alcoholic fatty liver disease. It aims to help avoid invasive tests like liver biopsy.
This study tests how well primary care doctors can screen for advanced liver scarring in people with fatty liver from non-alcohol causes or from alcohol use. It may help find liver problems earlier so you can get the right follow-up.
This study is creating better ways to measure if liver scarring from NASH (a type of fatty liver disease) has improved. It may help doctors know if treatments are working.
Hear when a new Liver Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.